Quarterly Consolidated Statement Of Cash Flows

D.Western Therapeutics Institute, Inc. - Filing #7727473

Concept 2017-01-01 to
2017-12-31
As at
2017-12-31
2017-01-01 to
2017-12-31
2016-01-01 to
2016-12-31
2016-01-01 to
2016-12-31
As at
2016-12-31
As at
2015-12-31
Quarterly consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-1,605,843,000 JPY
-1,494,873,000 JPY
-304,463,000 JPY
-173,541,000 JPY
Depreciation
45,118,000 JPY
17,557,000 JPY
Impairment losses
1,040,000,000 JPY
JPY
Increase (decrease) in allowance for doubtful accounts
JPY
5,824,000 JPY
Interest expenses
5,402,000 JPY
JPY
Foreign exchange losses (gains)
6,235,000 JPY
-22,183,000 JPY
Decrease (increase) in trade receivables
-19,750,000 JPY
-18,457,000 JPY
Decrease (increase) in inventories
11,318,000 JPY
-53,841,000 JPY
Other, net
-207,290,000 JPY
43,731,000 JPY
Subtotal
-791,624,000 JPY
-336,440,000 JPY
Interest and dividends received
2,676,000 JPY
3,990,000 JPY
Interest paid
-6,953,000 JPY
JPY
Income taxes paid
-1,313,000 JPY
-1,107,000 JPY
Net cash provided by (used in) operating activities
-797,215,000 JPY
-333,558,000 JPY
Cash flows from investing activities
Purchase of securities
JPY
-783,241,000 JPY
Purchase of property, plant and equipment
-3,897,000 JPY
-37,411,000 JPY
Proceeds from sale of investment securities
202,481,000 JPY
JPY
Net cash provided by (used in) investing activities
-763,123,000 JPY
-230,797,000 JPY
Cash flows from financing activities
Proceeds from long-term borrowings
582,000,000 JPY
JPY
Purchase of shares of subsidiaries not resulting in change in scope of consolidation
JPY
-4,800,000 JPY
Net cash provided by (used in) financing activities
1,406,969,000 JPY
1,066,537,000 JPY
Effect of exchange rate change on cash and cash equivalents
-5,886,000 JPY
22,595,000 JPY
Net increase (decrease) in cash and cash equivalents
-159,257,000 JPY
524,777,000 JPY
Cash and cash equivalents
2,132,677,000 JPY
2,291,934,000 JPY
1,767,157,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.